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ABSTRACT: Quantitative assessment of affinity and kinetics is a
critical component in the development of (receptor-targeted)
radiotracers. For fluorescent tracers, such an assessment is
currently not yet applied, while (small) changes in chemical
composition of the fluorescent component might have substantial
influence on the overall properties of a fluorescent tracer. Hybrid
imaging labels that contain both a radiolabel and a fluorescent dye
can be used to evaluate both the affinity (fluorescent label) and
the in vivo distribution (radiolabel) of a targeted tracer. We
present a hybrid label oriented and matrix-based scoring approach
that enabled quantitative assessment of the influence of (overall) charge and lipophilicity of the fluorescent label on the (in vivo)
characteristics of αvβ3-integrin targeted tracers. Systematic chemical alterations in the fluorescent dye were shown to result in a
clear difference in the in vivo distribution of the different hybrid tracers. The applied evaluation technique resulted in an
optimized targeted tracer for αvβ3-integrin, which combined the highest T/M ratio with the lowest uptake in other organs.
Obviously this selection concept would also be applicable during the development of other (receptor-targeted) imaging tracers.
■ INTRODUCTION
Clinical image-guided surgery trials suggest that a hybrid
surgical guidance approach, which utilizes both the radioactive
and fluorescent signatures of a single tracer (as demonstrated
by, e.g., the sentinel node tracer indocyanine green-99mTc-
nanocolloid),1−3 holds great promise.4 For this concept to be
suitable for the targeting of tumor-specific receptors, it needs to
be expanded via the addition of in vivo vectors, such as peptide
ligands, nanobodies, and/or antibody fragments.5
Peptides have proven to be fairly ideal imaging vectors since
they can be produced at relatively low cost and they can be
synthetically adapted. Moreover, they can be modified to target
a range of biomarkers and imaging applications.6 Preferably,
conjugation of an imaging label to the peptide-based vector
should not negatively alter the compounds targeting capabilities
and in vivo characteristics. Radioisotopes can be included in a
relatively straightforward manner via either covalent introduc-
tion (e.g., 18F; PET) or the incorporation of a chelate (e.g.,
DTPA or DOTA). The latter allows coordination of a
radioisotope suitable for either PET (e.g., 68Ga) or SPECT
(e.g., 99mTc and 111In) imaging. For fluorescence imaging,
incorporation of, or labeling with, a fluorescent dye is
mandatory. Here, organic dyes are favored over, e.g., inorganic
fluorescent quantum dots due to their smaller size (<1 nm), the
absence of (possibly) toxic metals, and their ability to be
tailored for conjugation to biomolecules. Yet, to date, “lack of
toxicity” and “clinically approved” are often the predominant
selection criteria for the conjugation of dyes (e.g., CW800 and
ZW800) to in vivo vectors. The physical characteristics of the
dye that relate to the signal intensity (e.g., quantum yield and
molar absorption coefficient) and stability are seldom taken
into account. Simultaneously, quantitative assessment of the
effect that is exerted by a fluorescent label on the affinity and
specificity of a (peptide-based) vector is commonly lacking as
fluorescence-based assessment of the in vivo kinetics is
hampered by tissue attenuation of both the excitation and
emission light.7−9 Such quantitative evaluation can be
performed via radiolabeling.
We previously developed an αvβ3-integrin specific hybrid
tracer that was functionalized with both 111In-DTPA and
CyAL-5.5b. This tracer demonstrated a high tumor-to-muscle
ratio (T/M-ratio; 9.02 ± 3.81) and allowed image-guided
resection of both the primary tumor and the distant
metastases.10 Unfortunately, in this tracer the fluorescent
component largely dictated the in vivo characteristics,10 an
effect that was also reported for other in vivo vectors.7,8,11−15
Further studies in this area are therefore warranted.
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Integrins are transmembrane receptors that play an
important role in cell−cell and cell−extracellular matrix
interactions.16,17 Especially αvβ3-integrin is involved in the
repair of damaged vasculature and the formation of new blood
vessels.17 Overexpression of αvβ3-integrin has been linked to
several angiogenesis-related diseases, such as rheumatoid
arthritis, osteoporosis, and cancer.18 In cancer, αvβ3-integrin is
linked to tumor invasiveness and the formation of metastases.19
αvβ3-integrin has therefore been used as a biomarker for the
development of optical20,21 and nuclear imaging tracers, of
which some have been evaluated in clinical trials (e.g., 99mTc-
NC100692, 18F-Galacto-RGD,22 18F-fluciclatide,23,24 and 18F-
alfatide).25 Cyclic RGD peptides (e.g., c[RGDyK]) drive the
receptor affinity in these structures.10,26,27 These peptides
tolerate broad structural modifications of the lysine side chain
while maintaining affinity for the target receptor.28
To quantitatively assess the influence of the fluorescent dye
on the characteristics of a targeted tracer, we synthesized a
range of hybrid tracers wherein the chemical design of the
fluorescent label is the only variable. The synthesized hybrid
c[RGDyK]-peptides were used for in vitro and in vivo
targeting, and the in vivo characteristics of these tracers were
evaluated via a matrix based scoring system.
■ RESULTS AND DISCUSSION
A matrix-based scoring system for αvβ3-integrin targeted hybrid
tracers was developed (Figure 1; Table 1). In this matrix the
chemical design of the fluorescent dye was varied systemati-
cally. Of the available cyanine dyes (Cy3, Cy5, and Cy7), Cy5
(n = 1; Figure 1) was selected for this initial evaluation based
on its recent successful use in an image-guided surgery trial,9
favorable emission profile (λex 650 nm; λem 670 nm), high
extinction coefficient (∼250 000 M−1 cm−1), high quantum
yield in aqueous solutions (∼0.25), and versatility as a synthetic
platform. Nonetheless, the approach demonstrated here should
also be easily translated to cyanine derivatives with a
polymethine chain of different length. Variations in the
chemical design of the Cy5-derivatives included the alkylation
of the indole-nitrogen and substitution of the aromatic ring.
This systematic variation of the Cy5 design resulted in nine
Cy5-derivatives with differences in overall charge (−2 to +2),
number of charges (1 to 4), and predicted hydrophilicity (logP)
(−4.71 to 3.95).29
The different Cy5-derivatives were incorporated into a
standardized hybrid imaging label comprising a peptide scaffold
and a DTPA chelate. Subsequently, the hybrid labels were
conjugated to c[RGDyK], leading to the formation of the
hybrid targeted tracers 4−12 (Figure 1). The conjugation of
the hybrid label to the targeting peptide resulted in an overall
charge for the complete tracer ranging from −3 to +1, assuming
a neutral charge for the c[RGDyK] and a charge of −1 for
DTPA (with or without chelated 111In3+).30 The chemical
characteristics of the tracers are included in Table 1. All studied
Cy5-derivatives incorporated into the hybrid tracer proved to
be stable upon exposure to serum for 24 h (Figure S1).31 A
hybrid label scaffold wherein no fluorescent dye was
incorporated (1), a sole DTPA chelate (2), and a non-
Figure 1. Structures of the αvβ3-integrin targeted tracers. (A) Structures of the standardized hybrid tracer (top structure) and the three reference
compounds used (1−3). (B) Incorporation of systematically modified Cy5-dyes (n = 1) into the hybrid label, resulting in tracers 4−12.












1 na na −0.54 −1
2 na na na −1
3 na na na +1
4 0 2 0.52 −1
5 +1 1 3.95 0
6 +2 2 0.27 +1
7 −1 3 −0.70 −2
8 0 2 −0.14 −1
9 +1 3 −3.81 0
10 −2 4 −1.93 −3
11 −1 3 −1.36 −2
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functionalized c[RGDyK] peptide (3) were used as reference
compounds.
The synthesized tracers and reference compounds were
evaluated in vitro for their affinity for αvβ3-integrin. Flow
cytometric analysis using epithelial-derived murine GEβ3 cells
that stably overexpress αvβ3-integrin revealed that conjugation
of the hybrid label to c[RGDyK] had little effect on the affinity
for αvβ3-integrin (Figure 2A).
32 Most of the tracers possessed a
similar affinity for αvβ3-integrin as the unlabeled parental
c[RGDyK] (3) (38.6 ± 4.3 nM), which could in turn be used
to block the receptor interactions (Figure S2). Direct
conjugation of the small DTPA-chelate to the lysine residue
of the RGD-peptide (2) resulted in a drop in affinity to 138.1 ±
27.2 nM. Introduction of the peptide-based scaffold of the
hybrid label in 1 seemed to restore the initial affinity (44.2 ±
5.9 nM). Strikingly, the presence of a single negatively charged
sulfonate group on the aromatic indole moiety of the Cy5-
derivative (7−9) yielded a similar receptor affinity as obtained
with the Cy5-derivatives that did not contain sulfonate groups
on the indole moiety (4−6). Hybrid labels that included a Cy5-
derivative with two sulfonate groups (10−12) showed the
lowest affinity (Figure 2A). An explanation for the lower affinity
of the hybrid tracers that contain a Cy5-derivative wherein two
sulfonate groups were included could not be found. Overall, 7
displayed the highest receptor affinity of the evaluated tracers
(21.9 ± 5.9 nM).
In vivo evaluation of the hybrid tracers was performed using
an orthotopic 4T1 breast cancer mouse model.10,33,34 Analysis
of the biodistribution of 1 nmol 111In-labeled (1 MBq) hybrid
tracer (4−12) or reference tracer (1,2) was performed at 24 h
post-injection to eliminate the presence of unwanted back-
ground activity caused by unbound circulating tracer.10 The
biodistribution of the compounds could be visualized using
whole-body SPECT imaging, as exemplified in representative
images in Figure 2C and D (see Figure S3 for a complete
overview of SPECT-based in vivo tracer distribution). The
fluorescent signature also allowed clear tumor identification via
fluorescence imaging, with low background fluorescence from
the intestine (Figure 2E). Assessment of the percentage of the
injected dose per gram of tissue (%ID/g) showed substantial
differences in the uptake of the tracers in the liver and kidneys
as well as in the T/M ratio (Figure 3).
To objectively assess the influence of the systematically
varied dye structure on the in vivo behavior of the various
hybrid tracers, an in vivo scoring system was developed. The
biodistribution data of hybrid tracers 2 and 4−12 were scored
relative to reference compound 1, which contained the hybrid
scaffold without a fluorescent label (Table 2; for scoring
parameters see SI). Significant improvements (p ≤ 0.05) in
desired effects (such as increased tumor uptake or reduced
nonspecific organ retention) are highlighted in green, whereas a
significant undesired effect (p ≤ 0.05) (e.g., increase in
background signal) is highlighted in red.
Compounds 4−11 showed superior tumor uptake compared
to reference compound 1. All studied hybrid tracers provided a
T/M-ratio >5 based on the detection of the radioisotope
(Figure 3). In line with previous (clinical) studies,35 this
indicates that there is sufficient contrast between the tumor and
the surrounding tissue to allow for fluorescence-based image-
guided surgery.
Table 2 and Figure 3 illustrate that incorporation of the
group of Cy5-derivatives with the highest predicted LogP
values (Table 1; 4−6) resulted in a significant increase in
nonspecific uptake in various tissues, which is line with previous
findings using an alternative hydrophobic Cy5 dye with a
similar LogP value.10 The addition of sulfonate groups to the
aromatic moiety of the dyes lowered the predicted LogP (7−
12; Table 1). In vivo this resulted in a reduction of the
background signal while the tumor uptake was retained.
Subsequently this yielded a higher imaging contrast (T/M-
ratio) (Table 2 and Figure 3). This effect was most prominent
for the Cy5-derivatives with a single sulfonate group (7−9).
The renal accumulation of tracers 4−12 appeared to be
related to the net charge of the Cy5-derivatives. In the series
5(+1) − 8(0) − 11(−1), 6(+2) − 8(0) − 10(−2), and 7(−1)
− 8(0) − 9(+1), the neutrally charged compound 8 displayed a
lower kidney accumulation compared to either negatively or
positively charged derivatives. While the neutrally charged 8
provides renal accumulation similar to that found for the non-
dye-containing 1 and 2, the neutral dyes 4 and 12 display a
higher accumulation in the kidneys. In 4, the SO3
− moiety is on
a “flexible” arm rather than one of the “rigid” aromatic units, a
subtle difference that seems to induce renal accumulation. This
effect is underlined by the fact that the series 4 − 7 − 10
displays the highest renal accumulation. In 12, the presence of
multiple charged groups, even though the overall dye is
neutrally charged, again seems to drive the renal accumulation
Figure 2. In vitro receptor affinity of the hybrid targeted tracers and in
vivo SPECT imaging. (A) In vitro affinity (fluorescence) of the
evaluated tracers toward αvβ3-integrin determined by flow cytometric
analysis (fluorescence). (B) Correlation between the in vitro affinity of
the hybrid tracers for αvβ3-integrin (fluorescence) and the T/M ratio
in vivo (radioisotope-based). Representative SPECT images of a 4T1-
tumor bearing mouse injected with a hybrid tracer showing (C) high
liver uptake (5) and (D) low liver uptake (8). Contours of the mouse
and tumor are represented by the dotted line. (E) T/M ratios of >5
(radioisotope-based) allowed accurate in vivo tumor visualization of
the tumor via fluorescence imaging (representative image after
injection of hybrid tracer 8).
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compared to 8. When combined, these observations show that
accumulation of these compounds in the kidneys is influenced
by the position as well as the number of charges present.
When combining the in vitro and in vivo analysis it can be
concluded that the hybrid tracers with Cy5 dyes that contain a
single aromatic sulfonate moiety (7−9) showed the highest
receptor affinity (Figure 2A), the most optimal tumor retention
(Table 2), and the highest T/M ratio (Figure 2B and 3). Of
these compounds, 8 stands out as it is the only hybrid tracer
with overall positive in vivo characteristics relative to the
reference compound (1) (Table 2). The Cy5 dyes without
aromatic sulfonate moieties (4−6) maintained a high receptor
affinity but yielded the lowest T/M ratios as a result of
increased nonspecific (Figure 3B). The Cy5 dyes with two
aromatic sulfonate moieties (10−12) showed the lowest
receptor affinity and T/M-ratios (Figures 2B and 3D).
In summary, it was shown that tracers with a fluorescent label
that have a moderately negative hydrophilicity (LogP), and
balanced charge distribution, can be used to improve the
biodistribution of the imaging tracer relative to the reference
radiotracers (1 and 2). The uniquely designed matrix approach
allowed the systematical evaluation of the different (hybrid)
imaging tracers in vivo.
Scoring of the imaging tracers allowed us to isolate the effect
of structural modification of the dyes on the in vivo
characteristics of the hybrid tracer. In our view, this concept
can have important implications for the design of alternative
imaging tracers in the future. The modular design of the hybrid
labels not only allows variation of the dye, but also allows
variation of the chelate or targeting ligand. Hence the presented
tracer optimization concept should also be applicable for the
introduction of PET- or therapeutic isotopes as well as other
targeting moieties directed against, e.g., cMET, CXCR4-
receptor, or PSMA.9,14,36 From this study it is evident that
the net properties, and especially the overall charge and the
charge distribution of the tracer, dictate the in vitro and in vivo
behavior. This extrapolates into the statement: “There is no
such thing as a universal imaging label that is suitable for all
targeting moieties.” In fact, it is highly likely that each individual
receptor-targeted vector will require a systematic evaluation of
the label that can realize specific imaging properties, being
either fluorescent, radioactive, or hybrid.
■ CONCLUSIONS
Hybrid imaging labels were shown to provide combined
quantitative assessment of both the affinity and in vivo
distribution of the tracers. This enabled systematic assessment
of the influence of the chemical modifications of the fluorescent
dye. The developed matrix-based scoring system showed a large
influence of relatively small changes in the chemical design of
fluorescent labels. This approach not only resulted in an
optimized αvβ3-integrin targeted hybrid tracer (tracer 8), but
also provides a systematic approach for the optimization of
other (hybrid) fluorescent tracers.
■ EXPERIMENTAL SECTION
Detailed synthesis description of the hybrid targeted imaging
agents and the in vitro and in vivo experiments is given in the
Supporting Information.
Figure 3. Radioisotope-based biodistribution of hybrid tracers 1, 2,
and 4−12 in 4T1-tumor bearing mice at 24 h p.i. (n = 6 for each
tracer). (A) Reference compounds: hybrid label scaffold (1) and
c[RGDyK]-DTPA (2). (B) Cy5-dyes without aromatic sulfonate
moiety (4−6). (C) Cy5-dyes with one aromatic sulfonate moiety (7−
9). (D) Cy5-dyes with two aromatic sulfonate moieties (10−12). (R =
see Figure 1A; R2 = −(CH2)3−SO3−, or −H, or −(CH2)2N+(CH3)3).
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